<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397211</url>
  </required_header>
  <id_info>
    <org_study_id>2019-303</org_study_id>
    <nct_id>NCT04397211</nct_id>
  </id_info>
  <brief_title>Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease</brief_title>
  <acronym>FLAVOUR II</acronym>
  <official_title>Comparison of Angiography-derived Fractional FLow Reserve- And IntraVascular Ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients With CoRonary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Hangzhou Normal University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi cardiovascular hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Angiography-derived Fractional FLow Reserve And IntraVascular Ultrasound-guided
      Intervention Strategy for Clinical OUtcomes in Patients with CoRonary Artery Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis is that angiography-derived FFR-guided strategy will show non-inferior
      rate of patients-oriented composite outcomes (POCO) at 12 months after randomization,
      compared with IVUS-guided strategy in patients with CAD.

      2. Study population and sample size calculation： Sample size calculation based on the event
      rates of previous trials, investigators predicted the rates of POCO at 12 months after PCI
      will be 7% in the Angiography-derived FFR-guided arm, and 8% in the IVUS-guided arm

        -  Primary endpoint: patient-oriented composite outcome (a composite of all-cause death,
           MI, any revascularization) at 12 months after PCI

        -  Design: non-inferiority, delta = 2.5%

        -  Sampling ratio: angiography-derived FFR-guided strategy: IVUS-guided strategy = 1:1

        -  Type I error (α): One-sided 2.5%

        -  Accrual time: 2 years

        -  Total time: 3 years (accrual 2 years + follow-up 1 years)

        -  Assumption: POCO 7.0% vs. 8.0% in angiography-derived FFR or IVUS-guided strategy,
           respectively

        -  Statistical power (1- β): 80%

        -  Primary statistical method: Kaplan-Meier survival analysis with log-rank test

        -  Estimated attrition rate: total 5%

        -  Stratification in Randomization: Presence of diabetes mellitus (35% of patients in each
           group) Based on the above assumption, we would need total 1,872 patients (936 patients
           in each group) with consideration of an attrition rate.

           3.Research Materials and Indication for Revascularization： For the angiography-derived
           FFR-guided strategy arm, Criteria for revascularization: angiography-derived FFR ≤ 0.80.
           For the IVUS-guided strategy arm, the criterion for revascularization is MLA ≤ 3mm2 or
           [3mm2 &lt; MLA ≤ 4mm2 and plaque burden &gt; 70%].
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-oriented composite outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Patient-oriented composite outcome (POCO), defined as a composite of all death, myocardial infarction (MI) or any revascularization at 12 months after randomization according to the ARC definitions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite outcome (POCO)</measure>
    <time_frame>24, 60 months</time_frame>
    <description>POCO at 24 and 60 months after randomization according to the ARC consensus
② Stent-oriented composite endpoint (a composite of cardiac death, target-vessel MI, or target lesion revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent-oriented composite endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Stent-oriented composite endpoint (a composite of cardiac death, target-vessel MI, or target lesion revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Cost-effectiveness analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiac death</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>All-cause and cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-vessel and all-cause nonfatal MI without peri-procedural MI</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Target-vessel and all-cause nonfatal MI without peri-procedural MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-vessel and all-cause nonfatal MI with peri-procedural MI</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Target-vessel and all-cause nonfatal MI with peri-procedural MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel/lesion revascularization (ischemia-driven or all)</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Target vessel/lesion revascularization (ischemia-driven or all)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target vessel/lesion revascularization (ischemia-driven or all)</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Non-target vessel/lesion revascularization (ischemia-driven or all)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization (ischemia-driven or all)</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Any revascularization (ischemia-driven or all)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (definite/probable/possible)</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Stent thrombosis (definite/probable/possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (ischemic and hemorrhagic)</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Stroke (ischemic and hemorrhagic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success of procedure (device, lesion and procedure)</measure>
    <time_frame>At discharge (1 week after index procedure)</time_frame>
    <description>Acute success of procedure (device, lesion and procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina severity measured with Seattle Angina Questionnaire (major centers only)</measure>
    <time_frame>12, 24 and 60 months</time_frame>
    <description>Angina severity measured with Seattle Angina Questionnaire (major centers only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1872</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Angiography-derived FFR-guided PCI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention using drug-eluting stent(s) will be performed by Angiography-derived FFR-guided strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVUS-guided PCI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention using drug-eluting stent(s) will be performed by IVUS-guided strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-derived FFR</intervention_name>
    <description>The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm
*Criteria for revascularization: Angiography-derived FFR ≤ 0.80</description>
    <arm_group_label>Angiography-derived FFR-guided PCI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVUS</intervention_name>
    <description>The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm
*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3&lt; MLA ≤ 4mm2 &amp; Plaque burden ≥ 70%</description>
    <arm_group_label>IVUS-guided PCI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ① Subject must be ≥ 18 years. ② Subject is able to verbally confirm understandings of
             risks, benefits and treatment alternatives of receiving invasive physiologic or
             imaging evaluation and PCI with a drug-eluting stent (DES) and he/she or his/her
             legally authorized representative provides written informed consent prior to any study
             related procedure. ③ Patients suspected with ischemic heart disease. ④ Patients with ≥
             50 stenosis by angiography-based visual estimation eligible for stent implantation. ⑤
             Target vessel size ≥ 2.5mm in visual estimation. ⑥ Target vessels are limited to major
             epicardial coronary arteries (left anterior descending artery[LAD], left circumflex
             artery [LCX], right coronary artery [RCA])

        Exclusion Criteria:

          -  ① The patient has a known hypersensitivity or contraindication to any of the following
             medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media
             (Patients with documented sensitivity to contrast media which can be effectively
             premedicated with steroids and diphenhydramine [e.g. rash] may be enrolled.) ②
             Patients with active pathologic bleeding. ③ Gastrointestinal or genitourinary major
             bleeding within the prior 3 months. ④ History of bleeding. diathesis, known
             coagulopathy (including heparin-induced thrombocytopenia). ⑤Non-cardiac co-morbid
             conditions with life expectancy &lt; 1 year. ⑥ Target vessel total occlusion. ⑦ Target
             lesion located in coronary arterial bypass graft. ⑧ Left main coronary artery stenosis
             ≥ 50%. ⑨ Not eligible for angiography-derived FFR (ostial RCA ≥ 50% stenosis,
             myocardial bridging, severe tortuosity, severe overlap, poor image quality)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JianAn Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bon-Kwon Koo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JianAn Wang, MD, PhD</last_name>
    <phone>+86 0571 87784808</phone>
    <email>wangjianan111@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinyang Hu, MD, PhD</last_name>
    <phone>+86 0571 87784808</phone>
    <email>hxy0507@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JianAn Wang, MD, PhD</last_name>
      <email>wangjianan111@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Guo, MD, PhD</last_name>
      <phone>13601234630</phone>
      <email>guo_li_jun@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianglong Chen, MD, PhD</last_name>
      <phone>13365910099</phone>
      <email>lianglongchen@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqing Yang, MD, PhD</last_name>
      <phone>13929530968</phone>
      <email>Whyn2000@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinyu Huang, MD, PhD</last_name>
      <phone>13819480927</phone>
      <email>hk0913@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinyang Hu, MD, PhD</last_name>
      <phone>+86 0571 87784808</phone>
      <email>hxy0507@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Jiang, MD, PhD</last_name>
      <phone>13588097533</phone>
      <email>13588097533@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Bu</last_name>
      <phone>13817577592</phone>
      <email>13817577592@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Yang</last_name>
      <phone>13546355355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Cardiovascular Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian An</last_name>
      <phone>15803518963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Chen</last_name>
      <phone>13506660597</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Zhou</last_name>
      <phone>13968801939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongzhen Fan, MD, PhD</last_name>
      <phone>18062418952</phone>
      <email>fanshizhang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Wook Nam, MD,PhD</last_name>
      <email>namcwcv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital,</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon-Kwon Koo, MD</last_name>
      <phone>82-2-2072-2062</phone>
      <email>bkkoo@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jinlong Zhang, MD</last_name>
      <phone>82-010-7440-1237</phone>
      <email>jinlong1102@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122. doi: 10.1016/j.jacc.2011.08.007. Epub 2011 Nov 7.</citation>
    <PMID>22070834</PMID>
  </results_reference>
  <results_reference>
    <citation>De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014 Sep 25;371(13):1208-17. doi: 10.1056/NEJMoa1408758. Epub 2014 Sep 1. Erratum in: N Engl J Med. 2014 Oct 9;371(15):1465.</citation>
    <PMID>25176289</PMID>
  </results_reference>
  <results_reference>
    <citation>Melikian N, De Bondt P, Tonino P, De Winter O, Wyffels E, Bartunek J, Heyndrickx GR, Fearon WF, Pijls NH, Wijns W, De Bruyne B. Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC Cardiovasc Interv. 2010 Mar;3(3):307-14. doi: 10.1016/j.jcin.2009.12.010.</citation>
    <PMID>20298990</PMID>
  </results_reference>
  <results_reference>
    <citation>Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bär F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007 May 29;49(21):2105-11. Epub 2007 May 17.</citation>
    <PMID>17531660</PMID>
  </results_reference>
  <results_reference>
    <citation>Westra J, Tu S, Campo G, Qiao S, Matsuo H, Qu X, Koltowski L, Chang Y, Liu T, Yang J, Andersen BK, Eftekhari A, Christiansen EH, Escaned J, Wijns W, Xu B, Holm NR. Diagnostic performance of quantitative flow ratio in prospectively enrolled patients: An individual patient-data meta-analysis. Catheter Cardiovasc Interv. 2019 Nov 1;94(5):693-701. doi: 10.1002/ccd.28283. Epub 2019 Apr 9.</citation>
    <PMID>30963676</PMID>
  </results_reference>
  <results_reference>
    <citation>Fearon WF, Achenbach S, Engstrom T, Assali A, Shlofmitz R, Jeremias A, Fournier S, Kirtane AJ, Kornowski R, Greenberg G, Jubeh R, Kolansky DM, McAndrew T, Dressler O, Maehara A, Matsumura M, Leon MB, De Bruyne B; FAST-FFR Study Investigators. Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. Circulation. 2019 Jan 22;139(4):477-484. doi: 10.1161/CIRCULATIONAHA.118.037350.</citation>
    <PMID>30586699</PMID>
  </results_reference>
  <results_reference>
    <citation>Westra J, Tu S, Winther S, Nissen L, Vestergaard MB, Andersen BK, Holck EN, Fox Maule C, Johansen JK, Andreasen LN, Simonsen JK, Zhang Y, Kristensen SD, Maeng M, Kaltoft A, Terkelsen CJ, Krusell LR, Jakobsen L, Reiber JHC, Lassen JF, Bøttcher M, Bøtker HE, Christiansen EH, Holm NR. Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study (Wire-Free Functional Imaging II). Circ Cardiovasc Imaging. 2018 Mar;11(3):e007107. doi: 10.1161/CIRCIMAGING.117.007107.</citation>
    <PMID>29555835</PMID>
  </results_reference>
  <results_reference>
    <citation>Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, Tebaldi M, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-Renteria H, Ronco F, Bøtker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. J Am Heart Assoc. 2018 Jul 6;7(14). pii: e009603. doi: 10.1161/JAHA.118.009603.</citation>
    <PMID>29980523</PMID>
  </results_reference>
  <results_reference>
    <citation>Collet C, Onuma Y, Sonck J, Asano T, Vandeloo B, Kornowski R, Tu S, Westra J, Holm NR, Xu B, de Winter RJ, Tijssen JG, Miyazaki Y, Katagiri Y, Tenekecioglu E, Modolo R, Chichareon P, Cosyns B, Schoors D, Roosens B, Lochy S, Argacha JF, van Rosendael A, Bax J, Reiber JHC, Escaned J, De Bruyne B, Wijns W, Serruys PW. Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. Eur Heart J. 2018 Sep 14;39(35):3314-3321. doi: 10.1093/eurheartj/ehy445. Erratum in: Eur Heart J. 2019 Jan 21;40(4):356.</citation>
    <PMID>30137305</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu B, Tu S, Qiao S, Qu X, Chen Y, Yang J, Guo L, Sun Z, Li Z, Tian F, Fang W, Chen J, Li W, Guan C, Holm NR, Wijns W, Hu S. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3077-3087. doi: 10.1016/j.jacc.2017.10.035. Epub 2017 Oct 31.</citation>
    <PMID>29101020</PMID>
  </results_reference>
  <results_reference>
    <citation>Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013.</citation>
    <PMID>27712739</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005 Apr 5;45(7):995-8.</citation>
    <PMID>15808753</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahn JM, Kang SJ, Yoon SH, Park HW, Kang SM, Lee JY, Lee SW, Kim YH, Lee CW, Park SW, Mintz GS, Park SJ. Meta-analysis of outcomes after intravascular ultrasound-guided versus angiography-guided drug-eluting stent implantation in 26,503 patients enrolled in three randomized trials and 14 observational studies. Am J Cardiol. 2014 Apr 15;113(8):1338-47. doi: 10.1016/j.amjcard.2013.12.043. Epub 2014 Jan 31. Review.</citation>
    <PMID>24685326</PMID>
  </results_reference>
  <results_reference>
    <citation>Nam CW, Yoon HJ, Cho YK, Park HS, Kim H, Hur SH, Kim YN, Chung IS, Koo BK, Tahk SJ, Fearon WF, Kim KB. Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional flow reserve-guided versus intravascular ultrasound-guided. JACC Cardiovasc Interv. 2010 Aug;3(8):812-7. doi: 10.1016/j.jcin.2010.04.016.</citation>
    <PMID>20723852</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834. doi: 10.1056/NEJMoa1700445. Epub 2017 Mar 18.</citation>
    <PMID>28317458</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, Tian N, Lin S, Lu Q, Wu X, Li Q, Liu Z, Chen Y, Qian X, Wang J, Chai D, Chen C, Li X, Gogas BD, Pan T, Shan S, Ye F, Chen SL. Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial. J Am Coll Cardiol. 2018 Dec 18;72(24):3126-3137. doi: 10.1016/j.jacc.2018.09.013. Epub 2018 Sep 24.</citation>
    <PMID>30261237</PMID>
  </results_reference>
  <results_reference>
    <citation>Park KW, Kang SH, Yang HM, Lee HY, Kang HJ, Cho YS, Youn TJ, Koo BK, Chae IH, Kim HS. Impact of intravascular ultrasound guidance in routine percutaneous coronary intervention for conventional lesions: data from the EXCELLENT trial. Int J Cardiol. 2013 Aug 10;167(3):721-6. doi: 10.1016/j.ijcard.2012.03.059. Epub 2012 Apr 4.</citation>
    <PMID>22481046</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang J, Koo BK, Hu X, Lee JM, Hahn JY, Yang HM, Shin ES, Nam CW, Doh JH, Lee BK, Ahn C, Wang J, Tahk SJ. Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial. Am Heart J. 2018 May;199:7-12. doi: 10.1016/j.ahj.2017.11.001. Epub 2017 Nov 6.</citation>
    <PMID>29754669</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289. Review.</citation>
    <PMID>29891620</PMID>
  </results_reference>
  <results_reference>
    <citation>ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, Williams DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 Jul;201:124-135. doi: 10.1016/j.ahj.2018.04.011. Epub 2018 Apr 21. Review.</citation>
    <PMID>29778671</PMID>
  </results_reference>
  <results_reference>
    <citation>Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.</citation>
    <PMID>32227755</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 17, 2020</study_first_submitted>
  <study_first_submitted_qc>May 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiography-derived fractional flow reserve</keyword>
  <keyword>Intravascular ultrasound</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Fractional flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The deidentified data will be shared after publication of first manuscript</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

